Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* AIM 1 (SURVEY) (AIM 1 is closed to enrollment)~* Cancer survivor~* Between 12 and 60 months after completion of cancer therapy (chemotherapy, radiation, hematopoietic cell transplant \[HCT\])~* Scheduled for a return clinic visit at one of the participating institutions~* English or Spanish-speaking~* Willing to provide informed consent/assent for study participation~* AIM 2 (VACCINE EVALUATION)~* Meets all inclusion criteria outlined in Aim 1~* Survey response indicated no prior history of HPV vaccination OR patient has no prior history of HPV vaccination by self - or parent/caregiver-report~* English or Spanish-speaking~* Medical clearance from treating clinician for study participation~* Agrees to return to participating institution for 3 HPV vaccine injections~* Willing to provide informed consent/assent for study participation~Exclusion Criteria:~* AIM 2 (VACCINE EVALUATION)~* Allergy to any component of the HPV vaccine including yeast and aluminum~* Thrombocytopenia (platelet count \< 50K) or coagulation disorder that would contraindicate intramuscular injection~* Transfusion of blood products or intravenous immune globulin within 3 months of study entry~* Female, and a) currently pregnant or lactating, or b) of childbearing potential and unwilling to avoid pregnancy during the vaccine phase of study (beginning at Day 1 and continuing until at least 4 weeks after all 3 vaccine doses have been administered)

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- Prevention (vaccine therapy) (Type: EXPERIMENTAL): Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).